Quick answer
What is the chemical structure of sermorelin? Sermorelin is the first 29 residues of human growth-hormone-releasing hormone with a C-terminal amide, formula C149H246N44O42S, average mass about 3,358 Da. It is made by solid-phase synthesis, purified by reverse-phase HPLC and supplied as a salt, usually trifluoroacetate or acetate. Its weak points are Met27 (oxidation), Asn8 (deamidation) and the N-terminal Tyr-Ala pair; identity is confirmed by mass spectrometry and purity by HPLC.
"Sermorelin" is often regarded as a single word with no structure behind it. It is a defined chemical entity: a 29-residue peptide amide whose atoms can be counted, whose mass can be calculated and whose likely impurities follow from its sequence. This article works through that structure from the formula on the product page, explains how such a peptide is made, and shows why the salt form matters as much as the sequence in a cell-based experiment. It is written for laboratory research use only; not for human consumption.
What the product page lists for sermorelin
The sermorelin product page describes a growth-hormone-releasing hormone fragment, GHRH (1-29), supplied as a lyophilized powder in 5 mg and 10 mg sizes. Purity is stated as ≥98% by HPLC, and batch documentation is published where available through the COA library. The page gives a molecular formula and a sequence, which is enough to do most of the chemistry in this article from first principles.
| Field | Product page entry | What it lets you check |
|---|---|---|
| Molecular formula | C149H246N44O42S | Calculated average mass of about 3,358 Da and a single sulfur atom, which belongs to the one methionine |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg | 29 residues; matches the first 29 residues of the native human sequence |
| Sizes | 5 mg and 10 mg | Starting mass for formula-based arithmetic (see the calculator) |
| Purity | ≥98% (HPLC) | Chromatographic purity, which is a different quantity from net peptide content |
| Supplied form | Lyophilized powder, sealed clear glass vial | Dry state is the most stable one for this sequence |
| Storage | Refrigerate at 2–8 °C; −20 °C for long-term; protect from heat, moisture and light | Two storage tiers; see the handling notes in the sermorelin research overview |
Two sizes are listed. The page does not state a counterion, so whether a given lot is an acetate, trifluoroacetate or other salt is a question for the certificate of analysis, not something to assume from the name. That point returns in the synthesis section below.
Reading the 29-residue sequence
Native human growth-hormone-releasing hormone is a 44-residue peptide with an amidated C-terminal leucine. Its sequence was determined from a pancreatic tumor that had caused acromegaly, and the tumor-derived peptide was shown to have full biological activity in vitro and in vivo as a stimulator of immunoreactive growth hormone release [1]. The same 44-residue sequence was later isolated from human hypothalamic tissue, confirming that the tumor product and the hypothalamic hormone are identical [2]. In a sequence analysis of the tumor peptide, the natural product, synthetic hpGRF(1-40)-OH, hpGRF(1-40)-NH2 and hpGRF(1-29)-NH2 showed equivalent activity in vitro, and the authors concluded that the C-terminal region does not contribute significantly to intrinsic activity or potency [3]. That finding is why a 29-residue fragment, rather than the full 44, became the standard research tool, and it is the compound this page sells.
Reading the sequence with chemistry in mind, a few positions stand out:
| Position(s) | Residue(s) | Chemical feature | Why it matters in the vial |
|---|---|---|---|
| 1–2 | Tyr-Ala | Free N-terminus followed by a small residue | Plasma dipeptidyl peptidase removes this pair from native GHRH; the resulting 3-44 product had less than 10-3 of the activity of the parent in one study [4] |
| 3 | Asp | Aspartyl residue next to Ala | Aspartyl residues can isomerize through a cyclic imide intermediate [5] |
| 8 | Asn | Asparaginyl residue next to Ser | Asparagine deamidation is the classic slow peptide degradation route [5] |
| 11, 20, 29 | Arg ×3 | Strongly basic guanidinium groups | Drive the positive charge at neutral pH and the tendency of the peptide to carry trifluoroacetate or acetate counterions |
| 12, 21 | Lys ×2 | Basic amines | Basic amines that contribute net positive charge |
| 1, 10 | Tyr ×2 | Aromatic side chains | Absorb at 280 nm; useful for UV-based concentration checks |
| 27 | Met | Thioether side chain | The one oxidation-prone residue; oxidation adds 16 Da per sulfoxide [6] |
| 29 | Arg-NH2 | C-terminal amide | Accounts for the hydrogens and nitrogen in the formula; the free acid would be 1 Da heavier |
The amide is worth checking, because it is easy to overlook. Summing the 29 residue formulas gives C149H243N43O42S; adding the three hydrogens and one nitrogen of an amidated terminus gives C149H246N44O42S, which is exactly the formula on the product page. A free-acid C-terminus would give C149H245N43O43S instead. The listed formula is therefore consistent with the amidated peptide, and mass spectrometry on an incoming lot should show it.
Mass arithmetic from the formula
From C149H246N44O42S the average molecular mass works out to about 3,357.9 g/mol and the monoisotopic mass to about 3,355.8 Da (both calculated with standard atomic masses; the certificate should report its own measured value). Those two numbers answer two different questions. The average mass is what converts milligrams to micromoles for solution making. The monoisotopic mass is the figure a high-resolution mass spectrometer reports for the lightest isotopologue peak, and it is the one to compare against an observed spectrum.
| Quantity | Formula | Note |
|---|---|---|
| Moles of peptide | mass (g) ÷ molar mass (g/mol) | Use 3,357.9 g/mol; this is a ceiling because counterions and water are included in the weighed mass |
| Molar concentration | moles ÷ volume (L) | Volume sets concentration; the mass in the vial is fixed |
| Mass concentration | molar concentration × 3,357.9 g/mol | 1 mM equals about 3.36 mg/mL |
Two cautions apply. First, the arithmetic assumes the powder is entirely peptide. Real lyophilized material also contains counterions and residual water, so the net peptide content is below the nominal mass; the molar figure is a ceiling. Second, the volume only sets the concentration, because the mass in the vial is fixed. The reconstitution calculator performs the same division, and peptide reconstitution volume calculations explains how to carry the figures through a dilution series.
How a 29-mer is made: solid-phase synthesis
A peptide of this length is made by solid-phase peptide synthesis. The method was introduced by Merrifield in 1963 with a tetrapeptide built on an insoluble resin [7]; the modern variant uses 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids, whose methodology, supports, linkers and side-chain protecting groups are reviewed by Fields and Noble [8]. The chain is assembled from the C-terminus toward the N-terminus, one residue per cycle, each cycle consisting of a deprotection step and a coupling step. For an amidated peptide the synthesis starts on a resin that releases a C-terminal amide when the finished chain is cleaved, which is how the terminal Arg-NH2 is produced.
Because every cycle is slightly less than 100% efficient, a 29-step synthesis accumulates side products: sequences missing one residue (deletions), chains that stopped early (truncations), and chains in which a protecting group was not fully removed. Reverse-phase HPLC separates most of these from the full-length product, and the main peak is what the stated purity percentage describes. Understanding HPLC purity explains why a percentage from a single method does not describe everything in the vial, and HPLC versus mass spectrometry explains why identity needs the second method.
Acetate, trifluoroacetate and why the salt form matters
Cleavage from the resin and reverse-phase purification both use trifluoroacetic acid, so a freshly purified cationic peptide is normally a trifluoroacetate (TFA) salt. For a peptide with five basic side chains and a free N-terminus, a considerable share of the powder mass can be counterion. Exchange to a weaker acid such as acetic acid is done by repeated lyophilization from acid, by ion-exchange resin or by RP-HPLC with an acetate-containing mobile phase, and a comparison of these approaches on the dicationic peptide lanreotide found that the HPLC and resin routes gave partial to almost complete exchange, while a deprotonation and reprotonation route removed trifluoroacetate completely [9]. That study also notes that residual trifluoroacetate can interfere with physicochemical characterization and may affect biological studies.
The biological point was made earlier. In fetal rat osteoblast cultures, TFA at 10-8 to 10-7 M reduced cell numbers and thymidine incorporation, and TFA salts of amylin and calcitonin produced less proliferation than the corresponding hydrochloride salts, which led the authors to recommend converting peptides to a hydrochloride or biologically equivalent salt before assessing biological effects [10]. For a researcher running cell-based assays with sermorelin, the practical conclusion is to find out which salt form the lot is, to keep it consistent between lots in a study, and to include a vehicle or counterion control where the readout is sensitive to proliferation.
| Question | Where to find the answer | If the answer is missing |
|---|---|---|
| Which counterion is the salt? | Certificate of analysis or supplier documentation | Ask in writing before starting a study that is sensitive to counterions |
| How much of the mass is peptide? | Net peptide content, from amino acid analysis or nitrogen content | Regard molar concentrations as upper bounds and note the uncertainty |
| Was exchange performed? | Supplier synthesis notes | Run a salt-matched vehicle control |
| Is the salt the same between lots? | Compare certificates lot to lot | Repeat the key assay with the new lot alongside the old one |
The name "sermorelin acetate" is common in the literature and refers to the acetate salt of the same 29-residue amide; it describes the counterion, not a different peptide.
Chemical weak points and how they would show up
With the sequence in hand, the degradation routes are predictable. None of them has been quantified for research-grade sermorelin in a public stability study, so the table describes what the chemistry implies and which measurement would reveal it, not measured rates.
| Route | Residue involved | Mass change | Detected by |
|---|---|---|---|
| Methionine oxidation | Met27 | +16 Da (sulfoxide), +32 Da (sulfone) | LC-MS; often a slightly earlier-eluting peak on RP-HPLC [6] |
| Asparagine deamidation | Asn8 | +0.984 Da | LC-MS with high resolution; shifted HPLC retention [5] |
| Aspartate isomerization | Asp3, Asp25 | None (isomer) | Shifted HPLC retention; same mass as the parent [5] |
| N-terminal truncation | Tyr1-Ala2 | −(Tyr+Ala) residues, 234 Da | LC-MS; the product is the 3-29 fragment, analogous to the plasma cleavage of native GHRH [4] |
| Aggregation or adsorption | Whole molecule | Loss of recoverable peptide | Concentration check against a standard curve; low-binding plastic reduces loss [11] |
General principles for protein and peptide stability, including the effect of pH, temperature and freezing, are summarized in reviews of protein pharmaceuticals [12][13], and the cold-storage rules on the product page follow from them. Lyophilization removes the water that most of these reactions need, which is why the dry vial is the stable state and why reconstituted peptides are handled differently.
A checklist for reading a sermorelin certificate
A certificate that has been read carefully is the best protection against receiving the wrong material. For sermorelin the useful questions are specific:
- Identity by mass. Is an observed mass reported, and is it close to 3,357.9 (average) or 3,355.8 (monoisotopic)? A value near 3,358 with a 16 Da satellite suggests partial methionine oxidation.
- Purity by HPLC. Is the method, wavelength and integration described, or only a percentage? Purity limits for peptides are set by compendial monographs that differ between pharmacopoeias, which is why a bare number is hard to interpret [14].
- Lot traceability. Does the lot number on the vial match the certificate it is read against?
- Test date. Is it recent relative to the shipping date?
- Counterion and net content. Are they stated? If not, record that gap.
How to read a COA walks through each field, and sermorelin purity testing applies the same logic to this compound specifically. For the sequence relationships among GHRH analogs, CJC-1295 versus sermorelin lists the four substitutions that distinguish the modified analog, and understanding amino acid sequences covers the notation used above.
All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.
Frequently asked questions
What is the chemical formula of sermorelin?
The product page lists C149H246N44O42S, which corresponds to the 29-residue GHRH (1-29) sequence with a C-terminal amide and works out to an average mass of about 3,358 Da.
Why is sermorelin only 29 amino acids when native GHRH has 44?
Studies of the tumor-derived peptide found that the 1-29 amide had in vitro activity equivalent to longer forms, so the C-terminal region was judged not to contribute significantly to intrinsic activity. The shorter peptide is also easier to synthesize.
Is sermorelin acetate a different compound from sermorelin?
No. Acetate is the counterion. The peptide chain is the same; the salt form can change the powder mass per mole of peptide and, in sensitive cell assays, the biological readout.
Does the V8 product page state the salt form?
No. The page lists formula, sequence, purity, form and storage but no counterion. The certificate or the supplier is the place to ask.
How do I confirm the identity of a sermorelin vial?
Compare an observed mass from LC-MS with the calculated 3,357.9 average or 3,355.8 monoisotopic value, and check that the HPLC main peak is the one that carries that mass. Sequence confirmation by fragmentation is stronger still.
Which residue is most vulnerable to oxidation?
Methionine at position 27 is the only thioether-bearing residue and the most oxidation-prone. Oxidation adds 16 Da per oxygen atom and can be seen by mass spectrometry.
Why do two sermorelin vials of the same nominal mass contain different amounts of peptide?
Nominal mass includes counterions and residual water. Net peptide content differs with salt form and lyophilization, so molar concentrations calculated from the label mass are upper bounds.
Is the calculated mass the same as the observed mass?
Close, not identical. The calculated figure uses standard atomic masses; an instrument reports a measured value with its own accuracy, and a deviation of a few parts per million is normal for high-resolution instruments.
What does lyophilized sermorelin look like?
A white to off-white cake or loose powder. Collapse, wet appearance or discoloration is noted in the receiving record. Peptide vial appearance explains the range.
Related reading: Sermorelin History: How GHRH (1-29) Was Discovered, Sermorelin In Vitro: Pituitary Cell Assay Models, Sermorelin Mechanism: GHRH Receptor and cAMP Signaling.
References
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-7. doi:10.1126/science.6812220
- Ling N, Esch F, Böhlen P, Brazeau P, Wehrenberg WB, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci U S A. 1984;81(14):4302-6. doi:10.1073/pnas.81.14.4302
- Spiess J, Rivier J, Thorner M, Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. Biochemistry. 1982;21(24):6037-40. doi:10.1021/bi00267a002
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-13. doi:10.1172/JCI112679
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-794. PMID: 3805008
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 1990;35(3):161-214. doi:10.1111/j.1399-3011.1990.tb00939.x
- Roux S, Zékri E, Rousseau B, Paternostre M, Cintrat JC, Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008;14(3):354-9. doi:10.1002/psc.951
- Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-83. doi:10.1152/ajpendo.1999.277.5.E779
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
